Sign in

CIK 0001095981 · Non-accelerated filer<br>Smaller reporting company

CERENOME, INC.

Sign in to watch
Ticker
CNSY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
330827593
Phone
737.255.7194
Business address
6420 LEVIT GREEN BOULEVARD, SUITE 310, HOUSTON, TX, 77021
Former names
PLUS THERAPEUTICS, INC., CYTORI THERAPEUTICS, INC., MACROPORE INC
  1. 4 Open-market buy Chief Financial Officer bought 10,000 shares at an average $2.55 ($25,494)
  2. 10-K Report Annual Report
  3. 8-K Event Results of operations
  4. SC 13G Stake Amended Statement of Ownership
  5. SC 13G/A Stake Amended Statement of Ownership
  6. 4 Open-market sale Chief Executive Officer sold 205,000 shares at an average $4.02 ($824,483)
  7. 4 Grant or award President - Asia Pacific acquired 51,825 shares (grant or award)
  8. 4 Grant or award Chief Financial Officer acquired 53,500 shares (grant or award)
  9. 4 Grant or award President acquired 61,850 shares (grant or award)
  10. 4 Grant or award Chief Executive Officer acquired 85,250 shares (grant or award)
  11. 4 Grant or award Director acquired 10,000 shares (grant or award)
  12. 4 Grant or award Director acquired 10,000 shares (grant or award)
  13. 4 Grant or award Director acquired 10,000 shares (grant or award)
  14. 4 Grant or award Director acquired 10,000 shares (grant or award)
  15. 4 Grant or award Director acquired 10,000 shares (grant or award)
  16. 4 Grant or award Director acquired 10,000 shares (grant or award)
  17. 4 Grant or award Director acquired 10,000 shares (grant or award)
  18. 4 Open-market buy President bought 6,000 shares at an average $2.15 ($12,880)
  19. 4/A Open-market buy Director bought 5,000 shares at an average $2.37 ($11,829)
  20. 4 Open-market buy Director bought 8,000 shares at an average $2.19 ($17,500)

Page 48 of 74 · 1,465 filings